GPI attending ISPOR 23 US, Boston

7-10 May 2023, Boston Convention Centre, Boston, USA

GPI will be attending ISPOR 23, held at the Boston Convention Centre, on 7-10 May 2023. GPI will be on stand 1039, and our representatives will be on hand to discuss how GPI can optimise your pricing and market access decision-making in 2022, 2023 and beyond. In addition we will be contributing to the research program, with five research posters. Details below!


ISPOR 23 welcomes all healthcare stakeholders and is directly relevant to researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, healthcare providers, and patient engagement organisations.

Visit our stand at ISPOR 23

Come and visit our stand (1039) to find out about THE ONLY value assessment and price prediction platform on the market! We will be providing demonstrations and discussing the platform, in addition to showcasing how the horizon methodology can minimise the risk of your drug launch, reduce time-intensive payer research and maximise commercial success.

In addition, find out how we utilise data from GPI pulse™ for value, price, and market access insights – with a live demos. Our GPI pulse™ product manager Margaret Labban will be at the conference to discuss and demonstrate how GPI pulse™ can help create more efficient, evidence-led market access strategies.

You will also be able to discuss pricing and market access challenges, stakeholder relationships discover innovative tools and solutions for the ecosystem. Most notably, GPI’s innovative suite of technological and service-based solutions, GPI pulse™ data analytics platform, and our unique platform solution, based on our award-winning methodology that quantifies an asset’s position in the market.


Research Posters

Value based price forecasting: An accurate method for orphan drugs?

Orphan products have increased evidence uncertainty for HTA decision-making. Therefore, HTA agencies have adopted orphan-specific pathways or considerations. However, as usually there is no appropriate comparator, forecasting price of novel orphan products with existing methods is challenging. This research aimed to determine accuracy of using a value-price model to forecast price of an orphan product across different payer archetypes.   


Determining the pricing checkpoints over an originator’s lifecycle in China

n China, while National Reimbursement Drug List (NRDL) inclusion is considered the best pathway to maximize originator’s market uptake, a “price for volume” strategy for considerable price cuts is common. Additionally, upon generic entry, originators may face further price cuts through volume-based procurement (VBP). The considerable price cuts and yearly rule changes have made understanding potential pricing outcomes in China a challenge. Therefore, this study aimed to determine the current important pricing checkpoints in China.  


US list prices for Maine’s high-cost highly prescribed drugs were over 7-fold higher than the cost of Canadian prices

US prescription drug prices are substantially higher than other countries. Many states rely on price transparency policies to highlight discrepancies between the US and other markets to indirectly help cut pharmaceutical spending. Maine state legislation passed in April 2022 aims to compare US WAC prices of the 100 most costly and 100 most frequently prescribed drugs to the lowest list price in Canada (Ontario, Quebec, British Columbia, and Alberta). From January 2023, Maine Health Data Organization (MHDO) will begin annually reporting potential savings if these drugs were subject to the Canadian reference price.


HTA Landscape of medical devices in Canada

Reimbursement of medical devices based on Heath Technology Assessment (HTA) has become increasingly important. In Canada, decision-making is highly decentralized, and evaluations of devices are not mandatory on a national level; local level stakeholders are the final decision-makers for reimbursement based on allocated budgets, clinical need, and healthcare objectives. This research aims to explore the current HTA landscape of medical devices in Canada.  

3

Share the Article:

Sign up to our mailing list to be informed of the latest webinars